Navigating drug coverage demands brain power in our DIY retirement system, and it isn’t getting any easier. While President Donald Trump has launched TrumpRx and other initiatives to lower costs, ...
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.
The agency zeroed in on claims that compounded GLP-1 drugs are comparable to approved medicines. Elsewhere, a blood pressure drug topped Wall Street expectations and a Merck deal paid dividends.
After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...
This biopharma company advancing cardiac drug candidates disclosed a notable insider sale amid late-stage clinical ...
Medtronic (NYSE: MDT) announced today that it entered into a definitive agreement to acquire Scientia Vascular in a $550 million deal.
The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center ...
Wall Street is drawing fresh lines across the large-cap biopharma landscape, initiating coverage on two stocks and maintaining an overweight rating on another.
Eton Pharmaceuticals. Eton Pharmaceuticals expands rare disease portfolio through acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution. Eton ...
John Bromels has been a contributing Motley Fool stock market analyst since 2012 covering information technology, communication services, industrials, energy, materials, utilities, and healthcare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results